BUY Conviction4/5 Analysis quality70/100 now
The YouTuber suggests Sarepta Therapeutics as a buy due to its recent expanded FDA approval for its muscular dystrophy drug Elevidys, which is expected to significantly boost annual revenue. The company also has a strong pipeline in RNA targeted therapies and gene therapy, with substantial projected revenue and earnings growth.
“The company just recently received an expanded approval from the FDA for its muscular destrophy drug elevas a drug that is expected to add another $2 billion to annual revenue within 2 years.”